PMDA — authorised 29 June 2020
- Marketing authorisation holder: Novartis Pharma K.K.
- Status: approved
🇯🇵 Mayzent in Japan
PMDA authorised Mayzent on 29 June 2020
Marketing authorisation
Mayzent in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in Japan
Frequently asked questions
Is Mayzent approved in Japan?
Yes. PMDA authorised it on 29 June 2020.
Who is the marketing authorisation holder for Mayzent in Japan?
Novartis Pharma K.K. holds the Japanese marketing authorisation.